$SKYH

BOSTON OMAHA Corp sold $3.6M of SKYH

BOSTON OMAHA Corp sold 360,000 shares of Sky Harbour Group Corp (SKYH) at $10.00 ($3.60M total) on 2026-08-11.

Original reporting
SEC EDGAR · BOSTON OMAHA Corp
Published Aug 14, 2026, 1:43 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 14, 2026, 2:42 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$SKYH
Neutral
medium confidence
Mentioned
$SKYH
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SKYHNeutralLow
01

Why it matters

A 10% owner sold 360,000 shares at $10.00/share on 2026-08-11, totaling $3.6M, with holdings after the transaction of 8,306,163 shares.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone is unlikely to drive a major repricing without accompanying fundamental news.

03

What to watch

The article does not state whether other insiders or the same holder have additional planned sales, nor does it provide context on total holdings change beyond the post-transaction share count.

Relevance 6/10Novelty 3/10Timing: filed 2026-08-13, sale dated 2026-08-11

Background

The article is a SEC Form 4 insider transaction disclosure for Sky Harbour Group Corp (SKYH).

Company-level read

Ticker impact

$SKYHNeutralMedium confidence
Context

Boston Omaha Corp, a 10% owner, filed a Form 4 showing an open-market sale of 360,000 SKYH shares for $3.6M.

Expected impact

Likely limited, short-lived sentiment impact unless follow-on selling continues or other disclosures emerge.

Evidence & confidence

This is a routine Form 4 open-market sale with no 10b5-1 plan stated, but the article provides no new operational, financial, or regulatory catalyst.

Market effects

No sector-level implications are provided; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

The sale may be liquidity-driven and not a bearish signal, especially since the filing does not cite any new negative company development.

Key entities

  • Sky Harbour Group Corp

    Subject of the Form 4 insider transaction disclosure.

  • Boston Omaha Corp

    10% owner who executed the open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SKYHMedAI 8/10

Sky Harbour announces $40 million equity financing deal

Sky Harbour Group (SKYH) entered a stock purchase agreement for a registered direct offering of 4,000,000 Class A common shares at $10.00 each, closing Aug. 12, 2026, for $40 million gross proceeds for general corporate purposes. A 90-day lock-up was agreed. Boston Omaha arranged a concurrent secondary sale of 360,000 shares at $10.00, expected to close Aug. 14, 2026.

$SKYHMed

Sky Harbour Group Corp (SKYH): Results of Operations and Financial Condition

Sky Harbour Group Corp (SKYH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sky Harbour Announces Q2 Results and Updates on Leasing, Construction, Funding and Other Activities Reaffirms Guidance for Year End 2026 WEST HARRISON, N.Y.--( BUSINESS WIRE )--Sky Harbour Group Corporation (NYSE: SKYH, SKYH WS) (“SHG” or the “Company”), an aviation

$SKYHMedAI 8/10

Skyhawk Therapeutics Releases Twelve-Month cUHDRS Subcomponent Results from its Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease

Skyhawk Therapeutics reported 12-month cUHDRS subcomponent results from its Phase 1/2 trial of oral Huntington’s disease candidate SKY-0515. Mean changes vs expected worsening (from Enroll-HD propensity-weighted analyses) were favorable for TFC (+0.07 vs -0.87), TMS (-2.00 vs 2.21), SDMT (-0.19 vs -1.78), and SWRT (+3.44 vs -3.13). CGI/PGI showed no assessed worsening and 65% of participants/50% of clinicians reported improvement; mHTT blood reductions up to 69% and PMS1 mRNA up to 26%.